Amarin’s Q1 Vascepa Sales Exceed Expectations, But Uncertainties Remain
Executive Summary
First quarter revenue of $150m beat analyst consensus of $129m, but investors remain wary of Amarin’s ability to overturn its recent Vascepa patent defeat and execute a favorable European strategy.